Table 1 Studies assessing clinical cardioprotective effects of SGLT2i by Cardiac Magnetic Resonance
Study | HF | Diabetes | SGLT2i | Duration of Therapy | Imaging Findings | ||
|---|---|---|---|---|---|---|---|
Santos-Gallego et al. [32] | HFrEF | No | Empaglifozin | 6 months | Improvement of LV volumes, LV mass, LV systolic function, functional capacity | ||
Brown et al. [91] | No | Yes | Dapaglifozin | 12 months | LVM Reduction | ||
Connelly et al. [94] | No | No | Empaglifozin | 6 months | No change in LV volumes and function | ||
Mason et al. [95] | No | Yes | Empaglifozin | 6 months | LVMi and ECV reduction | ||
Cohen et al. [96] | No | Yes | Empaglifozin | 6 months | Reduced EDV; No changes in ESV, EF, LVM or markers of cardiac fibrosis | ||
Hsu et al. [97] | No | Yes | Empaglifozin | 6 months | No improvement in LV function, structure, adiposity, and diffuse fibrosis | ||
Oldgren et al. [98] | No | Yes | Dapaglifozin | 6 weeks | Reduced LA volume. Decreased Peak global radial strain. No changes in peak global longitudinal and circumferential strains. Unchanged cardiac fatty acid uptake | ||
Verma et al. [99] | No | Yes | Empaglifozin | 6 months | LVMi Reduction | ||
Hundertmark et al. [101] | HFrEF/HFpEF | No | Empaglifozin | 12 weeks | No improvement in cardiac energetics (PCr/ATP) at rest and during stress | ||
Gaborit et al. [104] | No | Yes | Empaglifozin | 12 weeks | No change in LVM, LVEF, epicardial fat, diastolic function. | ||
Lee et al. [106] | HFrEF | Yes | Empaglifozin | 36 weeks | LV volumes reduction | ||
Singh et al. [107] | HFrEF/HFpEF | Yes | Dapaglifozin | 12 months | No effect on LV remodeling | ||